Texas Biomed Signs Agreement to Strengthen U.S. Biodefense Capabilities

Texas Biomedical Research Institute, one of the global leading independent biomedical research company intended to eradicating infection and developing health, an announced novel Cooperative Research and Development Agreement (CRADA) with the U.S. Department of War (DoW) to supports to protect service members and civilians from evolving and high-consequence biological challenges.

The agreement with the Capability Program Executive for Chemicl, Biological, Radiological and Nuclear Defense (CPE CBRND), which achieves the nation’s spending in chemical, biological, radiological, and nuclear (CBRN) defense diagnostics and medical countermeasures (MCMs), founds a collaborative framework to speed-up the advancement, testing, and validation of healthcare countermeasures while strengthening national preparedness.

“We are proud to offer our unique scientific capabilities to support the nation’s biodefense mission,” said Cory Hallam, Ph.D., Professor and Executive Vice President of Applied Science & Innovation (ASI) at Texas Biomed. “Texas Biomed excels in reducing the time between scientific insight and operational impact, which is critical for proactive preparedness and responding quickly when threats emerge.”

The CRADA founds a framework for Texas Biomed and CPE CBRND to collaborate on MCM projects which protect worldwide populations, involving U.S. warfighters serving at home and abroad. The arrangement recognizes Texas Biomed’s operational impact abilities, involving high containment research and devotion to Good Laboratory Practice (GLP) standards which support U.S. Food and Drug Administration (FDA) regulatory needs. The Institute is hub to one of the nation’s seven National Primate Research Centers, providing expertise in translational research and model advancement.

The CRADA framework is designed to confirms that significanyt resources for biological challenges, whether from naturally emerging diseases or engineered challenges, are continuously ready and available on demand, rather than occasionally.
 “This is a long-term investment in resilience,” said Larry Schlesinger, MD, President and CEO of Texas Biomed. “As biological threats continue to evolve, partnerships like this are increasingly essential. Under this agreement, we have the potential to build new, Joint capabilities that will serve the nation not just today, but for decades to come.”
 
According to Towards Healthcare, the biodefense market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 19.23 billion in 2026 to approximately USD 35.2 billion by 2035, representing a compound annual growth rate (CAGR) of 6.95% from 2026 to 2035, driven by, evolving of novel biotechnologies offers significance promise for biodefense, perticularly for significant objectives of biosurveillance and early warning, microbial forensics, challenges and threat assessment, horizon scanning in biotechnology, and medical countermeasure (MCM) advancement, scale-up, and delivery. Biodefense shields populations, agriculture, and ecosystems from biological threats, including infectious disease outbreaks, bioterrorism, and accidental pathogen releases. Its significant applications span digital early-warning technologies, rapid point-of-care diagnostics, well-developed medical countermeasures, environmental biosurveillance, and comprehensive emergency response planning. Biodefense increases the accelerated advancement of vaccines, antitoxins, and therapeutics. Advance technologies such as mRNA platforms, viral vectors, and AI-based drug discovery pipelines enables for the rapid formulation and mass manufacturing of countermeasures against new or modified pathogens. This confirms the safety of food supply chains and protects significant agricultural crops and livestock populations from destruction.

About Texas Biomedical Research Institute

Texas Biomedical Research Institute is a nonprofit research institute intended to protecting the wordwide community from infectious and long-term diseases. Via basic research, preclinical testing and novel partnerships, this company speed-up the advancement of diagnostics, therapies and vaccines for the world’s deadliest pathogens, including the first COVID-19 vaccine, the first Ebola treatment and the first Hepatitis C therapy. This organization is passionate related educating the next generation of bioscience leaders and confirming a healthier future for people.

A recent report by Towards Healthcare highlights that the biodefense market is growing as biodefense applies healthcare measures to protect patient against bioterrorism. This involves medicines and vaccinations. It involves healthcare research and preparations to defend against bioterrorist attacks. High-containment laboratories, stockpiles, and distribution networks shaped for biodefense serve as the rapid frontline defense against natural epidemics such as Ebola or influenza. Well-developed genomic sequencing enables researchers to trace the exact strain and geographic origin of a biological agent, giving intelligence agencies the definitive attribution needed to enforce international arms control agreements.